Discovery and structure-activity relationship of novel 2,3- dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2 h)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 Inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 13, 2014, Pages 5579-5601

  Patel, Maulik R ^a   Bhatt, Aaditya ^a   Steffen, Jamin D ^b   Chergui, Adel ^c   Murai, Junko ^c   Pommier, Yves ^c   Pascal, John M ^b   Trombetta, Louis D ^a   Fronczek, Frank R ^d   Talele, Tanaji T ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 2,3 DIHYDROBENZOFURAN 7 CARBOXYLIC ACID; 2,3 DIHYDROBENZOFURAN 7 CARBOXAMIDE; 2,3 DIHYDROBENZOFURAN 7 CARBOXAMIDE DERIVATIVE; 2,3 DIHYDROBENZOFURAN 7 CARBOXYLIC ACID; 2,5 DIMETHYL 2,3 DIHYDROBENZOFURAN 7 CARBOXYLIC ACID; 5 AMINO 2,3 DIHYDROBENZOFURAN 7 CARBOXAMIDE; 5 BROMO 2,3 DIHYDROBENZOFURAN 7 CARBOXAMIDE; 5 NITRO 2,3 DIHYDROBENZOFURAN 7 CARBOXAMIDE; AMIDE; BENZYLIDENE DERIVATIVE; BRCA2 PROTEIN; METHYL 2 (ALLYLOXY) 5 FLUOROBENZOATE; METHYL 2 (ALLYLOXY) 5 METHYLBENZOATE; METHYL 2 (ALLYLOXY)BENZOATE; METHYL 2 METHYL 2,3 DIHYDROBENZOFURAN 7 CARBOXYLATE; METHYL 2,5 DIMETHYL 2,3 DIHYDROBENZOFURAN 7 CARBOXYLATE; METHYL 3 ALLYL 2 HYDROXY 5 METHYLBENZOATE; METHYL 3 ALLYL 2 HYDROXYBENZOATE; METHYL 3 ALLYL 5 FLUORO 2 HYDROXYBENZOATE; METHYL 5 FLUORO 2 METHYL 2,3 DIHYDROBENZOFURAN 7 CARBOXYLATE; METHYL 5 FLUOROSALICYLATE; METHYL 5 METHYLSALICYLATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; CYTOTOXICITY; DNA DAMAGE; ELECTROPHILICITY; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; BENZOFURANS; CELL LINE; CHICKENS; DRUG DISCOVERY; ENZYME INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904325637     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5002502     Document Type: Article

References (67)

1. Gibson, B. A.; Kraus, W. L. New insights into the molecular and cellular functions of poly(ADPribose) and PARPs Nat. Rev. Mol. Cell Biol. 2012, 13, 411-424
2. Luo, X.; Kraus, W. L. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1 Genes Dev. 2012, 26, 417-432
3. Jankevicius, G.; Hassler, M.; Golia, B.; Rybin, V.; Zacharias, M.; Timinszky, G.; Ladurner, A. G. A family of macrodomain proteins reverses cellular mono-ADP-ribosylation Nat. Struct. Mol. Biol. 2013, 20, 508-514
4. Hottiger, M. O.; Hassa, P. O.; Luscher, B.; Schuler, H.; Koch-Nolte, F. Toward a unified nomenclature for mammalian ADP ribosyl transferases Trends Biochem. Sci. 2010, 35, 208-219
5. Rouleau, M.; Patel, A.; Hendzel, M. J.; Kaufmann, S. H.; Poirier, G. G. PARP inhibition: PARP1 and beyond Nat. Rev. Cancer 2010, 10, 293-301
6. Wacker, D. A.; Frizzell, K. M.; Zhang, T.; Kraus, W. L. Regulation of chromatin structure and chromatin dependent transcription by poly(ADP-ribose) polymerase-1: possible targets for drug-based therapies Subcell. Biochem. 2007, 41, 45-69
7. El-Khamisy, S. F.; Masutani, M.; Suzuki, H.; Caldecott, K. W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage Nucleic Acids Res. 2003, 31, 5526-5533 (Pubitemid 37441922)
8. Lan, L.; Nakajima, S.; Oohata, Y.; Takao, M.; Okano, S.; Masutani, M.; Wilson, S. H.; Yasui, A. In situ analysis of repair processes for oxidative DNA damage in mammalian cells Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13738-13743 (Pubitemid 39298477)
9. Okano, S.; Lan, L.; Tomkinson, A. E.; Yasui, A. Translocation of XRCC-1 and DNA ligase III-alpha from centrosomes to chromosomes in response to DNA damage in mitotic human cells Nucleic Acids Res. 2005, 33, 422-429 (Pubitemid 40276962)
10. Rossi, L.; Denegri, M.; Torti, M.; Poirier, G. G.; Scovassi, A. I. Poly(ADP-ribose) degradation by post-nuclear extracts from human cells Biochimie 2002, 84, 1229-1235 (Pubitemid 36372172)
11. Mangerich, A.; Burkle, A. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation Int. J. Cancer 2011, 128, 251-265
12. Penning, T.; Zhu, G.; Gandhi, V. B.; Gong, J.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E. F.; Donawho, C. K.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Osterling, D. J.; Olson, A. M.; Marsh, K. C.; Luo, Y.; Giranda, V. L. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H -benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer J. Med. Chem. 2009, 52, 514-523
13. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase Nature 2005, 434, 913-917 (Pubitemid 40559005)
14. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N. J.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M. B.; Jackson, S. P.; Smith, G. C. M.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005, 434, 917-921 (Pubitemid 40559006)
15. Kummar, S.; Chen, A.; Parchment, R. E.; Kinders, R. J.; Ji, J.; Tomaszewski, J. E.; Doroshow, J. H. Advances in using PARP inhibitors to treat cancer BMC Med. 2012, 10, 25
16. Curtin, N. J.; Szabo, C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond Mol. Aspects Med. 2013, 34, 1217-1256
17. Papeo, G.; Casale, E.; Montagnoli, A.; Cirla, A. PARP inhibitors in cancer therapy: an update Expert Opin. Ther. Pat. 2013, 23, 503-514
18. Underhill, C.; Toulmonde, M.; Bonnefoi, H. A review of PARP inhibitors: from bench to bedside Ann. Oncol. 2011, 22, 268-279
19. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of "BRCAness" in sporadic cancers Nat. Rev. Cancer 2004, 4, 814-819
20. Mendes-Pereira, A. M.; Martin, S. A.; Brough, R.; McCarthy, A.; Taylor, J. R.; Kim, J. S.; Waldman, T.; Lord, C. J.; Ashworth, A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol. Med. 2009, 1, 315-322
21. Patel, M. R.; Pandya, K. G.; Lau-Cam, C. A.; Singh, S.; Pino, M. A.; Billack, B.; Degenhardt, K.; Talele, T. T. Design and synthesis of N-substituted indazole-3-carboxamides as poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors Chem. Biol. Drug Des. 2012, 79, 488-496
22. Kulkarni, S. S.; Singh, S.; Shah, J. R.; Low, W. K.; Talele, T. T. Synthesis and SAR optimization of quinazoline-4(3 H)-ones as poly(ADP-ribose)polymerase-1 inhibitors Eur. J. Med. Chem. 2012, 50, 264-273
23. Langelier, M. F.; Plank, J. L.; Roy, S.; Pascal, J. M. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1 Science 2012, 336, 728-732
24. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic J. Med. Chem. 2010, 53, 4561-4584
25. Steffen, J. D.; Brody, J. R.; Armen, R. S.; Pascal, J. M. Structural implications for selective targeting of PARPs Front. Oncol. 2013, 3, 301-315
26. Donawho, C. K.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S.; Grimm, D. R.; Guan, R.; Han, E. K.; Holley-Shanks, R. R.; Hristov, B.; Idler, K. B.; Jarvis, K.; Johnson, E. F.; Kleinberg, L. R.; Klinghofer, V.; Lasko, L. M.; Liu, X.; Marsh, K. C.; McGonigal, T. P.; Meulbroek, J. A.; Olson, A. M.; Palma, J. P.; Rodriguez, L. E.; Shi, Y.; Stavropoulos, J. A.; Tsurutani, A. C.; Zhu, G. D.; Rosenberg, S. H.; Giranda, V. L.; Frost, D. J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin. Cancer Res. 2007, 13, 2728-2737 (Pubitemid 46795129)
27. Jones, P.; Altamura, S.; Boueres, J.; Ferrigno, F.; Fonsi, M.; Giomini, C.; Lamartina, S.; Monteagudo, E.; Ontoria, J. M.; Orsale, M. V.; Palumbi, M. C.; Pesci, S.; Roscilli, G.; Scarpelli, R.; Schultz-Fademrecht, C.; Toniatti, C.; Rowley, M. Discovery of 2-{4-[(3 S)-piperidin-3-yl]phenyl}-2 H -indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors J. Med. Chem. 2009, 52, 7170-7185
28. Thomas, H. D.; Calabrese, C. R.; Batey, M. A.; Canan, S.; Hostomsky, Z.; Kyle, S.; Maegley, K. A.; Newell, D. R.; Skalitzky, D.; Wang, L. Z.; Webber, S. E.; Curtin, N. J. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial Mol. Cancer Ther. 2007, 6, 945-956 (Pubitemid 46554564)
29. Menear, K. A.; Adcock, C.; Boulter, R.; Cockcroft, X. L.; Copsey, L.; Cranston, A.; Dillon, K. J.; Drzewiecki, J.; Garman, S.; Gomez, S.; Javaid, H.; Kerrigan, F.; Knights, C.; Lau, A.; Loh, V. M., Jr.; Matthews, I. T.; Moore, S.; O'Connor, M. J.; Smith, G. C.; Martin, N. M. 4-[3-(4- Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H -phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1 J. Med. Chem. 2008, 51, 6581-6591
30. Penning, T. D.; Zhu, G.; Gandhi, V. B.; Gong, J.; Thomas, S.; Lubisch, W.; Grandel, R.; Wernet, W.; Park, C. H.; Fry, E. H.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E. F.; Donawho, C. K.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Olson, A. M.; Marsh, K. C.; Luo, Y.; Rosenberg, S. H.; Giranda, V. L. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1 H -benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer Bioorg. Med. Chem. 2008, 16, 6965-6975
31. Griffin, R. J.; Calvert, A. H.; Curtin, N. J.; Newell, D. R.; Golding, B. T. Benzoxazole-4-carboxamides and their use in inhibiting poly(ADP-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy. PCT. Int. Appl. WO 9524379 A1 19950914, 1995.
32. Gangloff, A. R.; Brown, J.; de Jong, R.; Dougan, D. R.; Grimshaw, C. E.; Hixon, M.; Jennings, A.; Kamran, R.; Kiryanov, A.; O'Connell, S.; Taylor, E.; Vu, P. Discovery of novel benzo[ b ][1,4]oxazin-3(4 H)-ones as poly(ADP-ribose)polymerase inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 4501-4505
33. Lednicer, D.; Sun, J. H. Preparation of benzo[ b ]furan-7-carboxamides as antiemetic or antipsychotic agents. Eur. Pat. Appl. 234872, 1987.
34. Hogberg, T.; Paulis, T.; Johansson, L.; Kumar, Y.; Hall, H.; Ogren, S. Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy- N -[(1-ethyl-2- pyrrolidinyl)methyl]benzamide and related compounds. A comparative study J. Med. Chem. 1990, 33, 2305-2309 (Pubitemid 20236682)
35. Meyers, A.; Reuman, M.; Gabel, R. A. Nucleophilic annulations of aromatics. Novel route to benzo-fused ring systems via oxazoline activation J. Org. Chem. 1981, 46, 783-788
36. Meshram, H. M.; Premalatha, K.; Rameshbabu, K.; Eeshwaraiah, B.; Yadav, Y. S. Zirconium(IV) chloride catalyzed cyclization of ortho-allylphenols: synthesis of 2-methyl-2,3-dihydrobenzofurans Synth. Commun. 2004, 34, 3091-3097 (Pubitemid 39350070)
37. Rozenberg, V.; Dubrovina, N.; Sergeeva, E.; Antonov, D.; Belokon, Y. An improved synthesis of (S)-(+)- and (R)-(-)-[2.2]paracyclophane-4-carboxylic acid Tetrahedron: Asymmetry 1998, 9, 653-656
38. Irie, R.; Noda, K.; Ito, Y.; Matsumoto, N.; Katsuki, T. Catalytic asymmetric epoxidation of unfunctionalized olefins using chiral (salen)manganese(III) complexes Tetrahedron: Asymmetry 1991, 2, 481-494
39. He, Q.; Gomma, H.; Rohani, S.; Zhu, J.; Jennings, M. Chiral discrimination in diastereomeric salts of chlorine-substituted mandelic acid and phenylethylamine Chirality 2010, 22, 707-716
40. Stein, A. R.; Dawe, R. D.; Sweet, J. R. Preparation of chiral 1-phenylethanols and bromides Can. J. Chem. 1985, 63, 3442-3448
41. Riether, D.; Harcken, C.; Razavi, H.; Kuzmich, D.; Gilmore, T.; Bentzien, J.; Pack, E. J. J.; Souza, D.; Nelson, R. M.; Kukulka, A.; Fadra, T. N.; Zuvela-Jelaska, L.; Pelletier, J.; Dinallo, R.; Panzenbeck, M.; Torcellini, C.; Nabozny, G. H.; Thomson, D. S. Nonsteroidal dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics J. Med. Chem. 2010, 53, 6681-6698
42. Hadj-esfandiari, N.; Navidpour, L.; Shadnia, H.; Amini, M.; Samadi, N.; Faramarzi, M. A.; Shafiee, A. Synthesis, antibacterial activity, and quantitative structure-activity relationships of new (Z)-2- (nitroimidazolylmethylene)-3(2 H)-benzofuranone derivatives Bioorg. Med. Chem. Lett. 2007, 17, 6354-6363 (Pubitemid 47552849)
43. Zlatoidsky, P.; Maliar, T. Synthesis and structure-activity relationship study of the new set of trypsin-like proteinase inhibitors Eur. J. Med. Chem. 1999, 34, 1023-1034 (Pubitemid 30035906)
44. Pielichowski, J.; Popielarz, R. Trichloroethylene in organic synthesis: II. Reaction of trichloroethylene with secondary amines Tetrahedron 1984, 40, 2671-2675
45. Knoevenagel, E. Condensation of malonic acid with aromatic aldehydes with ammonia and amines J. Am. Chem. Soc. 1898, 31, 2596-2619
46. Scarpelli, R.; Boueres, J. K.; Cerretani, M.; Ferrigno, F.; Ontoria, J. M.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Jones, P. Synthesis and biological evaluation of substituted 2-phenyl-2 H -indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 488-492
47. Ferraris, D.; Ficco, R. P.; Pahutski, T.; Lautar, S.; Huang, S.; Zhang, J.; Kalish, V. Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones Bioorg. Med. Chem. Lett. 2003, 13, 2513-2518 (Pubitemid 36830762)
48. Varma, R.; Varma, M. Alumina-mediated condensation. A simple synthesis of aurones Tetrahedron Lett. 1992, 33, 5937-5940
49. Lea, T. V.; Suhb, J. H.; Kimb, N.; Park, H. In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells Bioorg. Med. Chem. Lett. 2013, 23, 2642-2646
50. Murai, J.; Huang, S. N.; Das, B. B.; Renaud, A.; Zhang, Y.; Doroshow, J. H.; Ji, J.; Takeda, S.; Pommier, Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res. 2012, 72, 5588-5599
51. Wahlberg, E.; Karlberg, T.; Kouznetsova, E.; Markova, N.; Macchiarulo, A.; Thorsell, A. G.; Pol, E.; Frostell, Å.; Ekblad, T.; Öncü, D.; Kull, B.; Robertson, G. M.; Pellicciari, R.; Schüler, H.; Weigelt, J. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors Nat. Biotechnol. 2012, 30, 283-288
52. Murai, J.; Huang, S. N.; Renaud, A.; Zhang, Y.; Ji, J.; Takeda, S.; Morris, J.; Teicher, B.; Doroshow, J. H.; Pommier, Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol. Cancer Ther. 2014, 13, 433-443
53. Cohen, M. L.; Lacefield, W. B. Preparation of 5-HT3 antagonist. Eur. Pat. Appl. 307172 A2 19890315, 1989.
54. 1) receptor antagonists J. Med. Chem. 2009, 52, 4161-4172
55. Rhoads, S. J.; Raulins, R.; Reynolds, R. D. The para -Claisen rearrangement. I. The preparation and rearrangement of the α- and γ-ethylallyl ethers of methyl -cresotinate. A reinvestigation J. Am. Chem. Soc. 1954, 76, 3456-3463
56. Nagarapu, L.; Aneesa; Satyender, A.; Chandana, G.; Bantu, R. Synthesis and antimicrobial activity of novel analogs of trifenagrel J. Heterocycl. Chem. 2009, 46, 195-200
57. Katz, L.; Karger, L. S.; Schroeder, W.; Cohen, M. S. Hydrazine derivatives. I. Benzalthio- and bisbenzaldithiosalicoylhydrazides J. Org. Chem. 1953, 18, 1380-1402
58. Ouach, A.; Gmouh, S.; Pucheault, M.; Vaultier, M. Onium salt supported organic synthesis in water: application to Grieco's multicomponent reaction Tetrahedron 2008, 64, 1962-1970
59. Ohno, T.; Ogawa, K.; Yano, S.; Fukushima, M.; Suzuki, N.; Asao, T. Synthesis and structure-activity relationship of 4-substituted benzoic acids and their inhibitory effect on the biosynthesis of fatty acids and sterols Arch. Pharm. 2005, 338, 147-158 (Pubitemid 40733779)
60. Keelara, A.; Srinivasa, G. R.; Channe, G. D. Palladium-catalyzed simple and efficient hydrogenative cleavage of azo compounds using recyclable polymer-supported formate Can. J. Chem. 2005, 83, 517-520 (Pubitemid 41039298)
61. Maede, Y.; Shimizu, H.; Fukushima, T.; Kogame, T.; Nakamura, T.; Miki, T.; Takeda, S.; Pommier, Y.; Murai, J. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel Mol. Cancer Ther. 2014, 13, 214-220
62. Steffen, J. D.; Tholey, R. M.; Langelier, M. F.; Planck, J. L.; Schiewer, M. J.; Lal, S.; Bildzukewicz, M. A.; Yeo, C. J.; Knudsen, K. E.; Brody, J. R.; Pascal, J. M. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer Cancer Res. 2014, 74, 31-37
63. Langelier, M. F.; Plank, J. L.; Servent, K. M.; Pascal, J. M. Purification of human PARP-1 and PARP-1 domains from Escherichia coli for structural and biochemical analysis Methods Mol. Biol. 2011, 780, 209-226
64. Winter, G. Xia2: an expert system for macromolecular crystallography data reduction J. Appl. Crystallogr. 2010, 43, 186-190
65. Winn, M. D.; Isupov, M. N.; Murshudov, G. N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement Acta Crystallogr. 2001, D57, 122-133 (Pubitemid 32062682)
66. Flack, H. D. On enantiomorph-polarity estimation Acta Crystallogr. 1983, A39, 876-881
67. Hooft, R. W.; Straver, L. H.; Spek, A. L. Determination of absolute structure using Bayesian statistics on Bijvoet differences J. Appl. Crystallogr. 2008, 41, 96-103